[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 903 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
H. RES. 903

    Expressing support for the designation of November as ``Complex 
   Regional Pain Syndrome and Reflex Sympathetic Dystrophy Syndrome 
                           Awareness Month''.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           November 20, 2025

 Mr. Tonko (for himself and Mrs. Miller-Meeks) submitted the following 
 resolution; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                               RESOLUTION


 
    Expressing support for the designation of November as ``Complex 
   Regional Pain Syndrome and Reflex Sympathetic Dystrophy Syndrome 
                           Awareness Month''.

Whereas Complex Regional Pain Syndrome, also known as Reflex Sympathetic 
        Dystrophy Syndrome, is a rare, neuro-inflammatory syndrome characterized 
        by intense chronic pain, swelling, vascular changes, and functional 
        impairment of the limbs that may result from simple trauma, injury, 
        infection, or surgery that can lead to disability;
Whereas Complex Regional Pain Syndrome can become debilitating unless diagnosed 
        early and treated appropriately;
Whereas although Complex Regional Pain Syndrome was first identified during the 
        American Civil War, it remains an obscure and poorly understood 
        condition for which there is no single test for diagnosis, and there is 
        no cure;
Whereas Complex Regional Pain Syndrome is more common in women than men with a 
        ratio of 3.5:1, with peak incidence in middle-aged and older adults, 
        especially post menopausal women;
Whereas the incidence of Complex Regional Pain Syndrome is low worldwide, with 
        regional rates generally between 5 and 29 per 100,000 individuals, 
        higher in women and older adults, and even lower in children;
Whereas individuals with Complex Regional Pain Syndrome, like many other rare 
        disorders, experience challenges with obtaining a diagnosis, limited 
        treatment options, and difficulty finding and accessing treatment 
        centers and physicians with expertise in Complex Regional Pain Syndrome;
Whereas because the disorder affects multiple systems of the body, a patient 
        with Complex Regional Pain Syndrome often requires access to care from 
        experts across a range of medical specialties;
Whereas, to date, there is no treatment for Complex Regional Pain Syndrome that 
        is approved by the Food and Drug Administration (in this resolution 
        referred to as the ``FDA'');
Whereas there is a critical need for research and development to advance 
        treatments for Complex Regional Pain Syndrome;
Whereas, as a result of the Orphan Drug Act, there have been important advances 
        in research on and treatment for rare diseases, including development 
        efforts in Complex Regional Pain Syndrome;
Whereas the FDA established the Accelerated Approval Pathway in 1992 and 
        Congress codified the pathway in 2012;
Whereas the Accelerated Approval Pathway is an important pathway for rare and 
        ultrarare diseases as it allows for ``earlier approval of drugs that 
        treat serious conditions, and fill an unmet medical need'';
Whereas Congress and the FDA have affirmed the importance of incorporating the 
        patient perspective throughout the drug review process through the FDA's 
        Patient-Focused Drug Development program;
Whereas the Reflex Sympathetic Dystrophy Syndrome Association, a nonprofit 
        organization founded in 1984 to provide support, education, and hope to 
        all affected by the pain and disability of CRPS/RSD, while driving 
        research to develop better treatments and a cure for Complex Regional 
        Pain Syndrome; and
Whereas ``Complex Regional Pain Syndrome and Reflex Sympathetic Dystrophy 
        Syndrome Awareness Month'' is expected to be observed in the United 
        States for years to come, providing hope and information for patients, 
        caregivers, and families around the country: Now, therefore, be it
    Resolved, That the House of Representatives--
            (1) expresses support for the designation of ``Complex 
        Regional Pain Syndrome and Reflex Sympathetic Dystrophy 
        Syndrome Awareness Month''; and
            (2) recognizes the importance of, with respect to Complex 
        Regional Pain Syndrome and Reflex Sympathetic Dystrophy 
        Syndrome Awareness Month--
                    (A) improving awareness;
                    (B) encouraging accurate and early diagnosis;
                    (C) advancing research;
                    (D) developing new treatments, diagnostics, and 
                cures; and
                    (E) identifying regulatory pathways for drug 
                development of ultrarare diseases like Complex Regional 
                Pain Syndrome and Reflex Sympathetic Dystrophy 
                Syndrome.
                                 <all>